| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006218607 |
| P356 | DOI | 10.1186/1742-4690-10-126 |
| P932 | PMC publication ID | 4228425 |
| P698 | PubMed publication ID | 24176092 |
| P5875 | ResearchGate publication ID | 258213123 |
| P50 | author | Anne-Mieke Vandamme | Q28743834 |
| Arnout Voet | Q56850113 | ||
| P2093 | author name string | Kristof Theys | |
| Soo-Yon Rhee | |||
| Jens Verheyen | |||
| Guangdi Li | |||
| P2860 | cites work | The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles | Q21245046 |
| The Protein Data Bank | Q24515306 | ||
| A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat | Q24606079 | ||
| HIV type 1 Gag as a target for antiviral therapy | Q24614498 | ||
| Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection | Q24672964 | ||
| A global approach to HIV-1 vaccine development | Q27024614 | ||
| Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein | Q27651983 | ||
| HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention | Q27666355 | ||
| Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein | Q27678471 | ||
| Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine series | Q27683977 | ||
| Maturation inhibitors: a new therapeutic class targets the virus structure | Q28256231 | ||
| SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building | Q29547665 | ||
| Global trends in molecular epidemiology of HIV-1 during 2000-2007. | Q30399382 | ||
| Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat | Q33864444 | ||
| Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
| Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein. | Q34567234 | ||
| Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain | Q34989840 | ||
| Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints. | Q35589028 | ||
| Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site | Q36508756 | ||
| Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. | Q36569418 | ||
| The structural biology of HIV-1: mechanistic and therapeutic insights | Q36656440 | ||
| Development of prophylactic vaccines against HIV-1. | Q37042563 | ||
| Nucleocapsid protein function in early infection processes | Q37086413 | ||
| Novel targets for antiretroviral therapy: clinical progress to date | Q37385347 | ||
| Molecular recognition in the human immunodeficiency virus capsid and antiviral design | Q38021264 | ||
| Human Immunodeficiency Virus Gag and protease: partners in resistance | Q38032330 | ||
| The NTD-CTD intersubunit interface plays a critical role in assembly and stabilization of the HIV-1 capsid | Q39180622 | ||
| Conservation among HSP60 sequences in relation to structure, function, and evolution | Q41728761 | ||
| Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools | Q42263635 | ||
| Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography | Q42712492 | ||
| Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors | Q42746719 | ||
| Identification of cavities on protein surface using multiple computational approaches for drug binding site prediction. | Q45936749 | ||
| Increased sequence diversity coverage improves detection of HIV-specific T cell responses | Q48076652 | ||
| Detecting hypermutations in viral sequences with an emphasis on G --> A hypermutation | Q73929271 | ||
| P304 | page(s) | 126 | |
| P577 | publication date | 2013-10-31 | |
| P1433 | published in | Retrovirology | Q15793508 |
| P1476 | title | Functional conservation of HIV-1 Gag: implications for rational drug design | |
| P478 | volume | 10 |
| Q35094794 | A new ensemble coevolution system for detecting HIV-1 protein coevolution. |
| Q30373040 | An integrated map of HIV genome-wide variation from a population perspective. |
| Q37253013 | Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q59351035 | Broad-Spectrum Antiviral Activity of an Ankyrin Repeat Protein on Viral Assembly against Chimeric NL4-3 Viruses Carrying Gag/PR Derived from Circulating Strains among Northern Thai Patients |
| Q91983821 | CA Mutation N57A Has Distinct Strain-Specific HIV-1 Capsid Uncoating and Infectivity Phenotypes |
| Q35795095 | CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba |
| Q34992565 | Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor |
| Q59355929 | Computational Design of Epitope-Enriched HIV-1 Gag Antigens with Preserved Structure and Function for Induction of Broad CD8 T Cell Responses |
| Q35201628 | Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex |
| Q28546549 | Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease |
| Q27324193 | Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. |
| Q91938838 | GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds |
| Q36096436 | Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance |
| Q26746070 | HIV Genome-Wide Protein Associations: a Review of 30 Years of Research |
| Q52578356 | HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data. |
| Q36672006 | HIV-1 Capsid Inhibitors as Antiretroviral Agents |
| Q34304136 | HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes |
| Q35761626 | HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors |
| Q38860284 | HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry. |
| Q38716274 | Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein |
| Q54204420 | Inhibitors of the HIV-1 capsid, a target of opportunity. |
| Q35664524 | Microplate-based assay for identifying small molecules that bind a specific intersubunit interface within the assembled HIV-1 capsid |
| Q49354408 | No evidence of ongoing evolution in replication competent latent HIV-1 in a patient followed up for two years |
| Q38370190 | Nucleocapsid Protein: A Desirable Target for Future Therapies Against HIV-1. |
| Q93058713 | Off-Pathway Assembly: A Broad-Spectrum Mechanism of Action for Drugs That Undermine Controlled HIV-1 Viral Capsid Formation |
| Q38897238 | Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen |
| Q93140697 | Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs |
| Q38230956 | Roles of HIV-1 capsid in viral replication and immune evasion |
| Q90438789 | Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy |
| Q92773004 | Specific inter-domain interactions stabilize a compact HIV-1 Gag conformation |
| Q40471717 | Structure of FIV capsid C-terminal domain demonstrates lentiviral evasion of genetic fragility by coevolved substitutions. |
| Q36259014 | The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa |